The safety and overall survival seen in the ARC-10 trial lends further support to the firm's strategy of pairing domvanalimab and zimberelimab with chemo in STAR-121.

Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination ...

Three phase 3 trials of combinations including datopotamab deruxtecan for the treatment of non–small cell lung cancer are beginning.

The drugmakers will explore the efficacy of Dato-DXd in combination with other drugs in PD-L1-expressing or EGFR-mutated NSCLC in these studies.

The first patients have been dosed in three global, randomized phase 3 trials evaluating the efficacy and safety of ...

Arcus Biosciences has a promising pipeline with five Phase 3 trials focused on GI and NSCLC cancers. Learn why RCUS stock ...

In the phase 1b combination study, a total of ten patients, nine of whom had progressed on prior anti-PD1/PD-L1 therapies were enrolled at doses of 3, 10, and 20 mg/kg. Patients remained on ...

League One: Matty Godden scores 97th-minute penalty to secure 2-2 draw for Charlton against Wrexham Wycombe ease past Leyton Orient 3-0 to move second, while Ben Wiles ensures a 2-0 victory for ...

Accumulating high-quality evidence reinforces the role of various immunotherapies—including PD-1 inhibitors, PD-L1 inhibitors, and bispecific antibodies targeting PD-1 plus CTLA-4—in combination with ...

Founded in 2015, the company has expedited the development of multiple investigational medicines into clinical studies, including new combination approaches that target TIGIT, PD-1, HIF-2a ...

In May, ivonescimab became the first PD-1/VEGF bispecific antibody to earn approval when Chinese regulators approved it to treat a genetically defined group of lung cancer patients. Summit ...